Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m2 or more.
Ard JD, Beavers DP, Hale E, Miller G, McNatt S, Fernandez A.
Surg Obes Relat Dis. 2019 Jul;15(7):1039-1043. doi: 10.1016/j.soard.2019.04.017.

Lorcaserin vs. Phentermine among non-surgical and surgical obese patients: Anthropometric, glycemic, lipid, safety and cost outcomes.
Elhag W, El Ansari W, Razaq S, Elsherif M, Mustafa I.
Ann Med Surg (Lond). 2019 Jul 13;45:75-81. doi: 10.1016/j.amsu.2019.07.024
 
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Tronieri JS, Wadden TA, Walsh OA, Berkowitz RI, Alamuddin N, Gruber K, Leonard S, Chao AM.
Metabolism. 2019 Jul;96:83-91. doi: 10.1016/j.metabol.2019.03.005

Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort.
Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, Desai J, Fitzpatrick SL, Horberg M, Koebnick C, Oshiro C, Yamamoto A, Young DR, Arterburn DE.
Obesity (Silver Spring). 2019 Apr;27(4):591-602. doi: 10.1002/oby.22430.

Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report.
Jo HS, Wang SM, Kim JJ.
Clin Psychopharmacol Neurosci. 2019 Feb 28;17(1):130-133. doi: 10.9758/cpn.2019.17.1.130.

Cardiovascular Safety During and After Use of Phentermine and Topiramate.
Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, Nguyen L, Thomas S, Cainzos-Achirica M, Rothman KJ, Andrews EB, Anthony MS.
J Clin Endocrinol Metab. 2019 Feb 1;104(2):513-522. doi: 10.1210/jc.2018-01010.

5-alpha-dihydrotestosterone elevations associated with phentermine use.
Pearson SM, Trujillo JM, McDermott MT.
Ther Adv Endocrinol Metab. 2018 May 20;9(8):255-258. doi: 10.1177/2042018818776158

Combination of venlafaxine and phentermine/topiramate induced psychosis: A case report.
Homola J, Hieber R.
Ment Health Clin. 2018 Mar 26;8(2):95-99. doi: 10.9740/mhc.2018.03.095.

Topiramate And Phentermine
Johnson DB, Quick J.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Mar 13.

Pharmacotherapy for obesity in individuals with type 2 diabetes.
Chukir T, Shukla AP, Saunders KH, Aronne LJ.
Expert Opin Pharmacother. 2018 Feb;19(3):223-231. doi: 10.1080/14656566.2018.1428558.

Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy.
Rebello CJ, Nikonova EV, Zhou S, Aronne LJ, Fujioka K, Garvey WT, Smith SR, Coulter AA, Greenway FL.
Obesity (Silver Spring). 2018 Feb;26(2):332-339. doi: 10.1002/oby.22094.

Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B, Mancini MC.
Expert Opin Drug Saf. 2017 Jan;16(1):27-39.

Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Halpern B, Faria AM, Halpern A.
Expert Rev Clin Pharmacol. 2013 May;6(3):235-41. doi: 10.1586/ecp.13.13.

Phentermine (2-methyl-1-phenylpropan-2-amine) is a sympathomimetic amine, a strong inhibitor of the vector of noradrenaline and works as an appetite suppressant by stimulating the neurons of the arched nucleus of the hypothalamic proopiomelanocortin.

It was approved by the U.S. Food and Drug Administration in 1959 and approved in 2012 in a combination of immediate-release phentermine and long-release topiramate, for the treatment of obese or overweight patients with comorbid conditions.

Topiramate (2, 3, 4, 5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate) is an antiepileptic, gamma-aminobutyric acid antagonist with the ability to inhibit compulsive desire for food and engaging behavior.

The phentermine/tocopyramate combination is a combination therapy (1) to be combined with a low-calorie diet and increased exercise to achieve effective weight loss in obesity (2).

Phentermine studies

Molecular Formula: C₁₀H₁₅N

Molecular Weight: 149.23 g/mol

CAS: 122-09-8  12674-13-4  9008-94-0

EC Number: 204-522-1

NSC Number: 759163

UN Number: 1851

UNII: C045TQL4WP

MDL number MFCD00059195

PubChem Substance ID 329820023

Sinonimi:

• Duromine
• Phenterminum
• Fentermina
• Normephentermine
• Mirapront
• Obermine
• Lonamin
• Phentrol
• Lipopill
• Fastin
• 1,1-Dimethyl-2-phenylethylamine
• 2-methyl-1-phenylpropan-2-amine
• Adipex-P
• 2-Phenyl-tert-butylamine
• 2-Amino-2-methyl-1-phenylpropane
• Phenyl-tert-butylamine
• alpha,alpha-Dimethylbenzeneethanamine
• alpha-Benzylisopropylamine
• Benzeneethanamine, alpha,alpha-dimethyl-
• Phenyl-tertiary-butylamine
• Ethanamine, 1,1-dimethyl-2-phenyl-

References______________________________________________

(1) New obesity agents: lorcaserin and phentermine/topiramate.  Fleming JW, McClendon KS, Riche DM.  Ann Pharmacother. 2013 Jul-Aug;47(7-8):1007-16. doi: 10.1345/aph.1R779.

(2) A Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study of a Fixed-Dose Combination of Phentermine/Topiramate in Adolescents with Obesity.  Hsia DS, Gosselin NH, Williams J, Farhat N, Marier JF, Shih W, Peterson C, Siegel R.  Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13910.